Timothy DeVere Cook - Sep 16, 2022 Form 4 Insider Report for Athenex, Inc. (ATNXQ)

Role
Chief Business and Commercial Officer, Proprietary Drugs
Signature
/s/Steven Adams, Attorney-in-Fact
Stock symbol
ATNXQ
Transactions as of
Sep 16, 2022
Transactions value $
-$224
Form type
4
Date filed
9/19/2022, 04:24 PM
Previous filing
Sep 12, 2022
Next filing
Sep 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATNXQ Common Stock Options Exercise +2.25K +18.42% 14.5K Sep 16, 2022 Direct F1
transaction ATNXQ Common Stock Tax liability -$224 -548 -3.79% $0.41* 13.9K Sep 16, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNXQ Restricted Stock Units Options Exercise $0 -2.25K -25% $0.00 6.75K Sep 16, 2022 Common Stock 2.25K Direct F1, F4
holding ATNXQ Stock Option (Right to Buy) 70K Sep 16, 2022 Common Stock 70K $17.29 Direct
holding ATNXQ Stock Option (Right to Buy) 30K Sep 16, 2022 Common Stock 30K $10.26 Direct F2
holding ATNXQ Stock Option (Right to Buy) 9K Sep 16, 2022 Common Stock 9K $3.56 Direct F3
holding ATNXQ Stock Option (Right to Buy) 75K Sep 16, 2022 Common Stock 75K $0.67 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of stock.
F2 This option vests in four equal annual installments beginning on August 27, 2021.
F3 This option vests in four equal annual installments beginning on September 16, 2022.
F4 The restricted stock units vest in four equal annual installments beginning on September 16, 2022.
F5 This option vests in four equal annual installments beginning on July 20, 2023.

Remarks:

Chief Business and Commercial Officer, Proprietary Drugs